Island Pharmaceuticals Surges on US Army Contract Extension

Island Pharmaceuticals has seen its stock price rally following a formal contract extension with the U.S. Army. The agreement focuses on the continued development of the company’s lead drug candidate, ISLA-101, a repurposed therapeutic targeting mosquito-borne viruses. By securing this extended partnership, the biotech firm gains critical validation and financial runway to advance its clinical pipeline, signaling strong confidence from government health authorities in their research objectives.